PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it posterior assistance.

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2

Complete if Known					
Application Number:	10/738,938				
Filing Date:	December 17, 2003				
First Named Inventor:	Raul G. Barletta				
Group Art Unit:	1652				
Examiner Name:	Allyson Purnett RAMIREZ, DELIA				
Attorney Docket Number:	801204-0003				

	-			U. S. PATENT DOCUMENTS		
		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines
Examiner Initials*	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
201		2003/0133952	Raul G. Barletta and Ofelia Barletta-Chacon	July 17, 2003		

				FOREIGI	N PATENT DOCUMENTS			
Examiner Initials*	Cite No.1	Office ³	Foreign Patent Docu	Mind Code ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant	Ţ
			None				Figures Appear	Ė

		OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS AND INFORMATION	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	12
Dr	•	BROWN, BARBARA A., et al., "Mycobacterium wolinskyi Sp. Nov. and Mycobacterium goodii Sp. Nov., Two New Rapidly Growing Species Related to Mycobacterium smegmatis and Associated with Human Would Infections: A Cooperative Study from the International Working Group on Mycobacterial Taxonomy", International Journal of Systematic Bacteriology. 1999, Vol. 49, p. 1493-1511.	
		HINGLEY-WILSON, SUZANNE M., et al., "Survival Perspectives from the World's Most Successful Pathogen, Mycobacterium tuberculosis", Nature Immunology. Oct. 2003, Vol. 4, No. 10, p. 949-955.	
		LAGIER, BEATRICE, et al., " Identification of Genetic Loci Implicated in the Survival of Mycobacterium smegmatis in Human Mononuclear Phagocytes", Molecular Microbiology. 1998, Vol. 29, No. 2, p. 465-475.	
		PIDDINGTON, DEBRA L., et al., "Cu,Zn Superoxide Dismutase of <i>Mycobacterium tuberculosis</i> Contributes to Survival in Activated Macrophages That Are Generating an Oxidative Burst", <i>Infection and Immunity</i> . Aug 2001, Vol. 69, No. 8, p. 4980-4987.	
m		HARTH, GUNTER, et al., "High-Level Heterologous Expression and Secretion in Rapidly Growing Nonpathogenic Mycobacteria of Four Major Mycobacterium tuberculosis Extracellular Proteins Considered To Be Leading Vaccine Candidates and Drug Targets", <i>Infection and Immunity</i> ,. June 1997, Vol. 65, No. 6, p. 2321-2328.	

Examiner	Date	1 1
Cianatura	Daio	10/11/86
Signature	Considered	1 /0//////

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanesse patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

	Complete if Known
Application Number:	10/738,938
Filing Date:	December 17, 2003
First Named Inventor:	Raul G. Barletta
Group Art Unit:	1652
Examiner Name:	Attyson Purnell RAMIREZ, DECLA
Attorney Docket Number:	801204-0003

	OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS AND INFORMATION
m	MacGOWAN, ALASDAIR, et al., "In Vitro Models, In Vivo Models, and Pharmacokinetics: What Can We Learn from In Vitro Models?", CID. 2001 Vol. 33 (Suppl 3), p. S214-S220.
	ORME, IAN M. and Collins, Frank M., "Mouse Model of Tuberculosis". Chapter 8, p. 113-134. <i>Tuberculosis: Pathogenesis, Protection and Control</i> , Barry R. Bloom (ed.), 1994, American Society for Microbiology, Washington, DC 20005.
	McMURRAY, DAVID N., "Guinea Pig Model of Tuberculosis". Chapter 9, p. 135-147. <i>Tuberculosis:</i> Pathogenesis, Protection and Control, Barry R. Bloom (ed.), 1994, American Society for Microbiology, Washington, DC 20005.
	DANNENBERG, JR., ARTHUR M., "Rabbit Model of Tuberculosis". Chapter 10, p. 149-156. <i>Tuberculosis: Pathogenesis, Protection and Control</i> , Barry R. Bloom (ed.), 1994, American Society for Microbiology, Washington, DC 20005.
	THOEN, CHARLES O. "Tuberculosis in Wild and Domestic Mammals". Chapter 11, p. 157-162. Tuberculosis: Pathogenesis, Protection and Control, Barry R. Bloom (ed.), 1994, American Society for Microbiology, Washington, DC 20005.
	JACOBS, JR., WILLIAM R. "Mycobacterium tuberculosis: A Once Genetically Intractable Organism", p. 1-16, Molecular Genetics of Mycobacteria, G.F. Hatful and W.R. Jacobs, Jr., (eds.)., 2000, ASM Press, Washington, D.C.
de	BARLETTA, RAUL G., et al. "Vaccines Against Intracellular Pathogens", Subcellular Biochemistry. 2000, Vol. 33, p. 559-599.

Examiner £	Date	10 / /2/
Signature	Considered	10/11/06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 4

Complete if Known Application Number: 10/738,938 Filing Date: December 17, 2003 First Named Inventor: Raul G. Barletta Group Art Unit: 1652 RAHIREZ, Examiner Name: Not Yet Assigned Attorney Docket Number: 801204-0003

				U. S	. PATENT DOCUMENTS				
Examiner Initials*	Cite No.1	U.S. Patent Doo	Kind Code ² (if known)	Na	ne of Patentee or Applicant of Cited Document	C	Pate of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	•
					/				
				/	<u></u>	-	· · · · · · · · · · · · · · · · · · ·		
				$\overline{}$	- //. •	4-			$\overline{}$
					150				_
				/					
			- / /	,	'\ '	+		/	
						+-		/	
					P				
			-A-1						
			$\overline{}$			+		<u>/</u>	
			/						
					\				
					/				
		/		-/V		+			
				$\overline{\cdot}$		+			
						IZ			
			(FOREI	GN PATENT DOCUMENTS	/			
Ī		Foreign F	atent Document	O FOREI	GN PATENT DOCUMENTS		T	. Pages Columns Lines	_
xaminer nitials*	Cite No. ¹	Office ³ Numb		Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Pocument		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear]
	\mathcal{A}		70						Ι
	4		-4-						4
-/			\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			-			╀
$\overline{/}$			γ,						╁
		10	,						
		1/0							╀
	\dashv	1			/			- 	╀
									+
Examin	or I		- D						_
Signatu			2/			ate onside	arad 10/	11/06	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


of 4

Sheet

Application Number:	10/738,938
Filing Date:	December 17, 2003
First Named Inventor:	Raul G. Barletta
Group Art Unit:	1652
Examiner Name:	Not Yet Assigned RAMIREZ, DELIA
Attorney Docket Number:	801204-0003

Complete if Known

		OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS AND INFORMATION						
xaminer iitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	1					
n		FENG, ZHENGYU, and Barletta, Raúl, "Roles of Mycobacterium smegmatis D-Alanine:D-Alanine Ligase D-Alanine Racemase in the Mechanisms of Action of and Resistance to the Peptidoglycan Inhibitor D-Cycloserine", Antimicrobial Agents and Chemotherapy. 2003, Vol. 47, No. 1, p. 283-291.						
		CHACON, OFELIA, et al., "Mycobacterium smegmatis D-Alanine Racemase Mutants Are Not Dependent on D-Alanine for Growth", Antimicrobial Agents and Chemotherapy. 2002, Vol. 46, No. 1, p. 47-54.						
		CÁCERES, NANCY E., et. al., "Overexpression of the D-Alanine Racemase Gene Confers Resistance to D-Cycloserine in <i>Mycobacterium smegmatis</i> ", <i>Journal of Bacteriology</i> . Aug. 1997, Vol. 179, No. 16, p. 5046-5055.						
		ZHENGYU, FENG, et. al., "Mycobacterium smegmatis L-Alanine Dehydrogenase (Ald) Is Required for Proficient Utilization of Alanine as a Sole Nitrogen Source and Sustained Anaerobic Growth", Journal of Bacteriology. Sept. 2002, Vol. 184, No. 18, p. 5001-5010.						
		KAMOGASHIRA, TAKASHI and Takegata, Setsuko, "A Screening Method for Cell Wall Inhibitors Using a D-Cycloserine Hypersensitive Mutant", <i>The Journal of Antibiotics</i> . June 1988, Vol. XLI, No. 6, p. 803-806.						
		STRYCH, ULRICH, et. al., "Characterization of the Alanine Racemases from Two Mycobacteria", FEMS Microbiology Letters. 2001, Vol. 196, p. 93-98.						
		COPIÉ, VALÉRIE, et al., "Inhibition of Alanine Racemase by Alanine Phosphonate: Detection of an Imine Linkage to Pyridoxal 5'—Phosphate in the Enzyme-Inhibitor Complex by Solid-State ¹⁵ N Nuclear Magnetic Resonance". <i>Biochemistry</i> , 1988, Vol. 27, p. 4966-4970.						
		HEATON, MICHAEL P., et. al, "Controlled Lysis of Bacterial Cells Utilizing Mutants with Defective Synthesis of D-Alanine", Can. J. Microbiol., 1988, Vol. 34, p. 256-261.						
		PATCHETT, ARTHUR A., et. al., "Antibacterial Activities of Fluorovinyl- and Chlorovinylglycine and Several Derived Dipeptides", <i>Antimicrobial Agents and Chemotherapy</i> . Mar. 1988, Vol. 32, No. 3, p. 319-323.						
		LAMBERT, MARY P., and Neuhaus, Francis C., "Mechanism of D-Cycloserine Action: Alanine Racemase from Escherichia coli W", <i>Journal of Bacteriology</i> . 1972, Vol. 110, No. 3, p. 978-987.						
		HOLS, PAXCAL, et. al, "Conversion of <i>Lactococcus Lactis</i> from Homolactic to Homoalanine Fermentation through Metabolic Engineering", <i>Nature Biotechnology</i> . June 1999, Vol. 17, p. 588-592.						
		TAUCH, ANDREAS, et. al., "The Alanine Racemase Gene alr is an Alternative to Antibiotic Resistance Genes in Cloning Systems for Industrial Corynebacterium Glutamicum Strains", Journal of Biotechnology. 2002, Vol. 99, p. 79-91.						
		ARIAS, CESAR A., et. al, "Serine and Alanine Racemase Activities of VanT: a Protein Necessary for Vancomycin Resistance in <i>Enterococcus Gallinarum</i> BM4174", <i>Microbiology</i> . 2000, Vol. 146, p. 1727-1734.						
De		THOMPSON, ROBERT J., et. al, "Pathogenicity and Immunogenicity of a Listeria monocytogenes Strain That Requires D-Alanine for Growth", Infection and Immunity. Aug. 1998, Vol. 66, No.8, p. 3552-3561.						



Appl. No 10/738938 Inventor: Barletta et al. Examiner: Raminez, Delia

1PE		Examiner: Ramire
UL 1 6 2004	N	HOLS, P., et. al., "The Alanine Racemase Gene is Essential for Growth of Lactobacillus plantarum", Journal of Bacteriology. June 1997, Vol. 179, No. 11, p. 3804-3807.
TRADENAME		NEIDHART, DAVID J., et. al., "X-ray Crystallographic Studies of the Alanine-specific Racemase from Bacillus stearothermophilus", The Journal of Biological Chemistry. 1987, Vol. 262, No. 32, p. 15323-15326.
THADS		BRAUNSTEIN, MIRIAM, et. al., "Genetic Methods for Deciphering Virulence Determinants of Mycobacterium tuberculosis", Virulence and Essential Gene Identification. 2002 p. 67-99.
		TYAGI, JAYA S. and Sharma, Deepak, "Mycobacterium smegmatis and Tuberculosis", TRENDS in Microbiology. February 2002, Vol. 10, No. 2, p. 68-69.
		DAVID, HUGO L., et. al., "Susceptibility of Mycobacterial D-Alanyl-D-Alanine Synthetase to D-Cycloserine", American Review of Respiratory Disease. 1969, Vol. 100, p. 579-581.
		NEUHAUS, FRANCIS C. "The Enzymatic Synthesis of D-Alanyl-D-alanine. I. Purification and Properties of D-Alanyl-D-Alanine Synthetase", <i>Journal of Biological Chemistry</i> . March 1962, Vol. 237, No. 3, p. 778-786.
		PETEROY, MARCY, et. al., "Characterization of a Mycobacterium smegmatic Mutant That Is Simultaneously Resistant to D-Cycloserine and Vancomycin", Antimicrobial Agents and Chemotherapy. June 2000, Vol. 44, No. 6, p. 1701-1704.
		MANNING, JAMES M., et. al., "Inhibition of Bacterial Growth by β-Chloro-D-Alanine", <i>Proc. Nat. Acad. Sci.</i> February 1974, Vol. 71, No. 2, p. 417-421.
		DAVID, SUZANA, "Synergic Activity of D-Cycloserine and β-Chloro-D-Alanine Against <i>Mycobacterium tuberculosis</i> ", Journal of Antimicrobial Chemotherapy. 2001, Vol. 47, p. 203-206.
		MARSHALL, C. GARY and Wright, Gerard D., "Dd1N from Vancomycin-Producing Amycolatopsis orientalis C329.2 Is a VanA Homologue with D-Alanyl-D-Lactate Ligase Activity", Journal of Bacteriology. Nov. 1998, Vol. 180, No. 21, p. 5792-5795.
		RASTOGI, NALIN, et. al., "Enhancement of Drug Susceptibility of Mycobacterium avium by Inhibitors of Cell Envelope Synthesis", Antimicrobial Agents and Chemotherapy. May 1990, Vol. 34, No. 5, p. 759-764.
		DUTKA-MALEN, SYLVIE, et. al., "Sequence of the vanC Gene of Enterococcus gallinarum BM4174 encoding a D-Alanine:D-Alanine Ligase-Related Protein Necessary for Vancomycin Resistance", Gene. 1992, Vol. 112, p. 53-58.
		BELANGER, AIMEE E. and Inamine, Julia M., "Genetics of Cell Wall Biosynthesis", <i>Molecular Genetics of Mycobacteria</i> . Hatfull, G.F. and Jacobs, W.R. (Eds.), ASM Press, Washington, D.C., 2000, p. 191-202.
		REITZ, RICHARD H., et. al., "The Biochemical Mechanisms of Resistance by Streptococci to the Antibiotics D-Cycloserine and O-Carbamyl-o-Serine", <i>Biochemistry</i> . Aug. 1967, Vol. 6, No. 8, p. 2561-2570.
		WALSH, CHRISTOPER T., "Enzymes in the o-Alanine Branch of Bacterial Cell Wall Peptidoglycan Assembly", Journal of Biological Chemistry. 1989, Vol. 264, No. 5, p. 2393-2396.
		DAVID, HUGO L., "Resistance to D-Cycloserine in the Tubercle Bacilli: Mutation Rate and Transport of Alanine in Parental Cells and Drug-Resistant Mutants", <i>Applied Microbiology</i> . May 1971, Vol;. 21, No. 5, p. 888-892
		ZYGMUNT, WALTER A., "Antagonism of D-Cycloserine Inhibition of Mycobacterial Growth By D-Alanine", J. Bacteriol. 1963, Vol. 85, p. 1217-1220.
	m	YEW, WING WAI, et. al., "Adverse Neurological Reactions in Patients with Multidrug-Resistant Pulmonary Tuberculosis After Coadministration of Cycloserine and Ofloxacin*, Clinical Infectious Diseases. August 1993, Vol. 17, 288-289.

Appl. No: 10/738938 Javentor: Barletta et al. Examiner: Raminez, Delia

m	KAUFMAN, DARRELL and Manley, William F., "A New Procedure for Determining DL Amino Acid Ratios in Fossels Using Reverse Phase Liquid Chromatography", 1998. <i>Quaternary Geochronology</i> , Vol. 17, p. 987-1000.	
du	NEUHAUS, FRANCIS C., "D-Cycloserine and O-Carbamyl-D-serine", Antibiotics - Vol. 1, Mechanism of Action. Gottlieb, D and Shaw, Paul D. (eds.), Springer-Verlag New York Inc., 1967, p. 40-83.	

Examiner Signature	Date Considered	10/11/06	
-----------------------	--------------------	----------	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.